Anisa Shaker, MD
Gastroenterology · Los Angeles, CANPI 1356524250
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $190 of the $313 with a category attached, or 60.8%. AstraZeneca accounts for 62.9% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for gastroenterology clinicians in CA, where the typical reported total is $1,790.
Across 3 payments — averaging $104.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$197
- Regeneron Healthcare Solutions, Inc.$116
Across 23 payments — averaging $6458.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$98K
- Regeneron$50K
What the payments were for
- Travel & lodging$12339%
- Food & beverage$19061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $197 |
| Regeneron Healthcare Solutions, Inc. | 1 | $116 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$313 in reported general payments places this provider in the 20th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VoqueznaVonoprazan Fumarate | 11 | $6,592 |
| Omeprazole | 96 | $1,200 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 17 | $252 |
| Famotidine | 18 | $117 |
| Ondansetron OdtOndansetron | 12 | $61 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Los Angeles
- Bennett RothLos Angeles$2.8M
- Sammy SaabLos Angeles$1.9M
- Sadeea AbbasiLos Angeles$556K
- Gil MelmedLos Angeles$467K
- Venkataraman MuthusamyLos Angeles$297K
- Caroline HwangLos Angeles$279K
- Adarsh ThakerLos Angeles$241K
- Andres YarurLos Angeles$218K
- Joseph PisegnaLos Angeles$210K
- Steven-Huy HanLos Angeles$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.